Inspired by the success of plerixafor and ulocuplumab and the complicated role of the CXCL12-CXCR4 axis in MM, more efforts are made to explore inhibitors, antagonists, and antibodies aimed at the interaction between CXCL12 and its receptor. Here, CXCR4 is linked to Miyoshi myopathy.